WO2023156956A1 - Composition for improving bone health - Google Patents
Composition for improving bone health Download PDFInfo
- Publication number
- WO2023156956A1 WO2023156956A1 PCT/IB2023/051451 IB2023051451W WO2023156956A1 WO 2023156956 A1 WO2023156956 A1 WO 2023156956A1 IB 2023051451 W IB2023051451 W IB 2023051451W WO 2023156956 A1 WO2023156956 A1 WO 2023156956A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vitamin
- composition
- range
- extract
- mcg
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 186
- 230000037180 bone health Effects 0.000 title claims description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 69
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 67
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 67
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 64
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229940016409 methylsulfonylmethane Drugs 0.000 claims abstract description 48
- 229910052796 boron Inorganic materials 0.000 claims abstract description 37
- 239000011575 calcium Substances 0.000 claims abstract description 37
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 37
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims abstract description 36
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 36
- 235000001465 calcium Nutrition 0.000 claims abstract description 36
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 35
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 35
- 239000010949 copper Substances 0.000 claims abstract description 35
- 229910052802 copper Inorganic materials 0.000 claims abstract description 35
- 239000000284 extract Substances 0.000 claims abstract description 35
- 239000011777 magnesium Substances 0.000 claims abstract description 35
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 35
- 239000011591 potassium Substances 0.000 claims abstract description 35
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 35
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 35
- 239000011718 vitamin C Substances 0.000 claims abstract description 35
- 239000011701 zinc Substances 0.000 claims abstract description 35
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 35
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims abstract description 34
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 34
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 34
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 34
- 235000019152 folic acid Nutrition 0.000 claims abstract description 34
- 239000011724 folic acid Substances 0.000 claims abstract description 34
- 229960000304 folic acid Drugs 0.000 claims abstract description 34
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 34
- 235000001055 magnesium Nutrition 0.000 claims abstract description 34
- 239000011719 vitamin A Substances 0.000 claims abstract description 34
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 34
- 229940046009 vitamin E Drugs 0.000 claims abstract description 34
- 239000011709 vitamin E Substances 0.000 claims abstract description 34
- 229940045997 vitamin a Drugs 0.000 claims abstract description 34
- 235000016804 zinc Nutrition 0.000 claims abstract description 34
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 33
- 241000195955 Equisetum hyemale Species 0.000 claims abstract description 33
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims abstract description 33
- PFRQBZFETXBLTP-UHFFFAOYSA-N Vitamin K2 Natural products C1=CC=C2C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C(=O)C2=C1 PFRQBZFETXBLTP-UHFFFAOYSA-N 0.000 claims abstract description 33
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 33
- DKHGMERMDICWDU-GHDNBGIDSA-N menaquinone-4 Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)=C(C)C(=O)C2=C1 DKHGMERMDICWDU-GHDNBGIDSA-N 0.000 claims abstract description 33
- 235000019155 vitamin A Nutrition 0.000 claims abstract description 33
- 239000011647 vitamin D3 Substances 0.000 claims abstract description 33
- 235000019143 vitamin K2 Nutrition 0.000 claims abstract description 33
- 239000011728 vitamin K2 Substances 0.000 claims abstract description 33
- 229940021056 vitamin d3 Drugs 0.000 claims abstract description 33
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims abstract description 32
- 229940024509 stinging nettle extract Drugs 0.000 claims abstract description 32
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 claims abstract description 32
- 235000005282 vitamin D3 Nutrition 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000018678 bone mineralization Effects 0.000 claims abstract description 25
- 241000124008 Mammalia Species 0.000 claims abstract description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 21
- 239000011707 mineral Substances 0.000 claims abstract description 21
- 229940088594 vitamin Drugs 0.000 claims abstract description 20
- 229930003231 vitamin Natural products 0.000 claims abstract description 20
- 235000013343 vitamin Nutrition 0.000 claims abstract description 20
- 239000011782 vitamin Substances 0.000 claims abstract description 20
- 239000011785 micronutrient Substances 0.000 claims description 76
- 235000013369 micronutrients Nutrition 0.000 claims description 76
- 239000000419 plant extract Substances 0.000 claims description 49
- 241000282414 Homo sapiens Species 0.000 claims description 47
- 210000000963 osteoblast Anatomy 0.000 claims description 34
- 235000010755 mineral Nutrition 0.000 claims description 20
- 230000000694 effects Effects 0.000 claims description 19
- 239000004615 ingredient Substances 0.000 claims description 18
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 14
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 14
- 235000015872 dietary supplement Nutrition 0.000 claims description 14
- 102000019307 Sclerostin Human genes 0.000 claims description 13
- 108050006698 Sclerostin Proteins 0.000 claims description 13
- 239000000443 aerosol Substances 0.000 claims description 12
- 108010010201 core binding factor alpha Proteins 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 230000000699 topical effect Effects 0.000 claims description 10
- 238000007911 parenteral administration Methods 0.000 claims description 9
- 208000001132 Osteoporosis Diseases 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 3
- 235000005473 carotenes Nutrition 0.000 claims description 3
- 230000003247 decreasing effect Effects 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 abstract description 15
- 208000020084 Bone disease Diseases 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 4
- 238000005115 demineralization Methods 0.000 abstract description 3
- 230000002328 demineralizing effect Effects 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 51
- 229940108928 copper Drugs 0.000 description 30
- 229960003975 potassium Drugs 0.000 description 30
- 238000009472 formulation Methods 0.000 description 21
- 239000003814 drug Substances 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- 230000033558 biomineral tissue development Effects 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 239000011159 matrix material Substances 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000003111 delayed effect Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- 239000012730 sustained-release form Substances 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000021317 phosphate Nutrition 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 206010065687 Bone loss Diseases 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000010478 bone regeneration Effects 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920006237 degradable polymer Polymers 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 239000013583 drug formulation Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019441 ethanol Nutrition 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000011369 resultant mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000012089 stop solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 235000009108 Urtica dioica Nutrition 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- HFVAFDPGUJEFBQ-UHFFFAOYSA-M alizarin red S Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=C(S([O-])(=O)=O)C(O)=C2O HFVAFDPGUJEFBQ-UHFFFAOYSA-M 0.000 description 2
- 239000002269 analeptic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 229940112869 bone morphogenetic protein Drugs 0.000 description 2
- -1 cachets Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000003589 local anesthetic agent Substances 0.000 description 2
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- COCAUCFPFHUGAA-MGNBDDOMSA-N n-[3-[(1s,7s)-5-amino-4-thia-6-azabicyclo[5.1.0]oct-5-en-7-yl]-4-fluorophenyl]-5-chloropyridine-2-carboxamide Chemical group C=1C=C(F)C([C@@]23N=C(SCC[C@@H]2C3)N)=CC=1NC(=O)C1=CC=C(Cl)C=N1 COCAUCFPFHUGAA-MGNBDDOMSA-N 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001582 osteoblastic effect Effects 0.000 description 2
- 210000004409 osteocyte Anatomy 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-L 4-nitrophenyl phosphate(2-) Chemical compound [O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-L 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108010072732 Core Binding Factors Proteins 0.000 description 1
- 102000006990 Core Binding Factors Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000028399 Critical Illness Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000195950 Equisetum arvense Species 0.000 description 1
- 239000005768 Equisetum arvense L. Substances 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 1
- 101150098533 SOST gene Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000219422 Urtica Species 0.000 description 1
- 244000274883 Urtica dioica Species 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037176 bone building Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- KQSBZNJFKWOQQK-UHFFFAOYSA-N hystazarin Natural products O=C1C2=CC=CC=C2C(=O)C2=C1C=C(O)C(O)=C2 KQSBZNJFKWOQQK-UHFFFAOYSA-N 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 229960005481 menatetrenone Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical class CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229960001309 procaine hydrochloride Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000026749 regulation of bone remodeling Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- MWNQXXOSWHCCOZ-UHFFFAOYSA-M sodium percarbonate Chemical compound [Na+].OOC([O-])=O MWNQXXOSWHCCOZ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- YFGAFXCSLUUJRG-WCCKRBBISA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCCN=C(N)N YFGAFXCSLUUJRG-WCCKRBBISA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 238000013271 transdermal drug delivery Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/22—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Definitions
- This application describes a composition containing a micronutrient and plant extract combination and method of using the same for improving bone health.
- Bone health is very important at every stage in life. Bone mineralization, repair and maintenance is a continuous process and requires good nutrition and exercise to keep it healthy. The body's skeleton forms and grows to its adult size in a process called modeling. It then completely regenerates — or remodels — itself about every 10 years. Remodeling removes old pieces of bone and replaces them with new, fresh bone tissue. This keeps the bone and its cells healthy and strong and allows the bones to supply calcium and other minerals to the body.
- Maintaining healthy bones requires a continuous supply of nutrients, many of which are not produced in a human body or are available in limited amounts only. These include vitamin C for forming proper collagen, the bone skeleton, which is subsequently hardened by the deposition of minerals. Also, bone building minerals such as calcium, other minerals and trace elements have to originate from dietary sources. Dietary supplementation with one or a few micronutrients does not assure optimum bone metabolism as each component has a different mechanism of action and interaction with other cellular compounds and can lead to metabolic imbalance. This is why there is a need for a selected and experimentally tested composition of essential nutrients that can be applied as a safe and effective measure, such as in a form of a supplement to prevent excessive bone loss and support healthy bone regeneration uniformly through the years.
- the object underlying the present invention is to provide a composition that is able to prevent or treat bone diseases, including osteoporosis, and that allows for a balanced bone remodeling in a mammal, preferably human.
- the composition shall prevent excessive bone loss and shall support healthy bone regeneration uniformly through the years of the live span of a mammal, preferably human.
- composition comprising: at least 4 vitamins, selected from the group consisting of vitamin C, vitamin A, vitamin E, vitamin D3, vitamin K2, and folic acid; at least 4 minerals, selected from the groups consisting of calcium, magnesium, boron, zinc, potassium, and copper; further comprising methylsulfonylmethane, horsetail extract, and stinging nettle extract.
- a composition which improves the bone mineralization of a mammal, preferably human, treated therewith.
- the composition when taken in by a mammal, preferably human, leads to a balanced bone remodeling and prevents the onset or propagation of bone diseases including osteoporosis.
- the composition prevents excessive bone loss and supports a healthy bone regeneration uniformly throughout the live span of a mammal, specifically human.
- composition comprises vitamins, (micronutrients), minerals, plant extracts and methylsulfonylmethane.
- the composition contains at least four vitamins, preferably at least five vitamins, most preferably all of the above-mentioned vitamins.
- one or two of the above-listed vitamins can be left out in the composition according to the present invention.
- only one vitamin of the above-mentioned list or none of the vitamins of the above-mentioned list is left out.
- the metals like calcium, magnesium, boron, zinc, potassium and copper are incorporated in the composition in the form of suitable compounds or salts of the listed elements.
- the listed elements stand for salts or compositions or compounds of these elements which are acceptable as a dietary supplement or in pharmaceutical compositions.
- the listed elements can be considered as minerals since they are typically employed in the form of a mineral containing the element or ion.
- the composition according to the present invention contains at least four or more, preferably at least five, most preferably all of the minerals listed above. Again, for the best effect, only one or none of the minerals is left out in the composition.
- the composition according to the present invention contains horsetail extract and stinging nettle extract, i.e. extracts from equisetum arvense and Urtica dioica. They can be obtained from natural sources by known extraction means. Methyl sulfonylmethane (MSM) is also known as dimethylsulfone. It is a dietary supplement that can be derived from biological sources or be prepared in a chemical synthesis.
- the composition comprising or consisting of the above ingredients as active ingredients can be used to improve bone mineralization, preferably in a mammal, especially human.
- the ingredients are present in the following amounts: Vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg- 1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg- 8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg.
- the composition is formulated for treating a mammal, preferably human, to improve the bone mineralization thereof.
- the composition comprises only micronutrients (or vitamins), plant extracts and minerals, including methylsulfonylmethane. Therefore, according to one embodiment of the invention, the composition consists of the vitamins, plant extracts, minerals and methyl sulfonylmethane as active ingredients and allows only for the presence of a carrier material, which is acceptable in dietary supplements and pharmaceutical compositions.
- a carrier material which is acceptable in dietary supplements and pharmaceutical compositions.
- a preferred composition consists of the above listed ingredients.
- the composition is formulated for oral, nasal, topical, rectal, vaginal, aerosol and/or parenteral administration.
- At least five vitamins selected from the group consisting of vitamin C, vitamin A, vitamin E, vitamin D3, vitamin K2 and folic acid are present and/or at least five minerals, selected from the group consisting of calcium, magnesium, boron, zinc, potassium and copper are present in the composition.
- the composition comprises or consists of vitamin C, vitamin A, Vitamin E, Vitamin D3, Vitamin K2, folic acid, calcium, magnesium, boron, zinc, potassium, copper, methyl sulfonylmethane, horsetail extract and stinging nettle extract.
- composition as a dietary supplement.
- a dietary supplement comprising a composition as defined above.
- a pharmaceutical composition comprising the composition as defined above, and optionally, a pharmaceutically acceptable carrier
- composition for use in the treatment of osteoporosis.
- composition or dietary supplement as defined above for improving the bone mineralization in a mammal.
- the invention also relates to a method of improving bone mineralization, preferably in a mammal, comprising: administering a composition, a dietary supplement or a pharmaceutical composition as outlined above.
- composition which comprises all of the above-listed vitamins, minerals, plant extracts and methyl sulfonyl methane.
- effects and ranges also relate to the subset of the ingredients as outlined above.
- composition is also described as a micronutrient and plant extract composition, which is intended to encompass the micronutrients or vitamins, plant extracts and minerals and methyl sulfonylmethane as outlined above for the composition.
- micronutrient and plant extract as a composition were used to treat, prevent, support, improve and enhance bone health.
- a physiological dose for a mammal was calculated based on daily consumption.
- the micronutrient and plant extract composition was packaged in drug formulation for easy consumption by mammals. The physiological calculations were based on in-vitro experiments and mode of delivery for consumption by human.
- the (micronutrient and plant extract) composition comprises of a vitamin C, vitamin A (preferably P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, zinc, potassium, copper, methyl sulfonylmethane (MSM), horsetail extract, and stinging nettle extract.
- a vitamin C preferably P-carotene
- vitamin E preferably P-carotene
- vitamin D3 vitamin K2
- folic acid calcium, magnesium, boron, zinc, potassium, copper, methyl sulfonylmethane (MSM), horsetail extract, and stinging nettle extract.
- MSM methyl sulfonylmethane
- the concentration of each ingredient in the (micronutrient and plant extract) composition are vitamin C in the range of 10 mg-20,000 mg, vitamin A (preferably P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of lmg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000mg and stinging nettle extract in range of 10 mg- 5,000 mg.
- vitamin C in the range of 10 mg-20,000 mg
- vitamin A preferably P-carotene
- a method of increasing bone mineralization by increasing alkaline phosphatase enzyme activity, core-binding factor alpha (1) transcription factor in mineralization of human osteoblasts and reducing sclerostin enzyme activity by administering the (micronutrient and plant extract) composition.
- FIG. 1 shows Alkaline phosphatase (ALP) activity in human osteoblasts after exposure to selected micronutrients and plant extracts.
- ALP Alkaline phosphatase
- FIG. 1 shows core-binding factor alpha 1 (Cbfa-1) detection in human osteoblasts after treatment with different micronutrients and plant extracts.
- Figure 3 shows mineralization level of human osteoblasts stimulated by different micronutrients and plant extracts.
- Figure 4 shows Sclerostin detection in human osteoblasts after treatment with different micronutrients and plant extracts.
- the (micronutrient and plant extract) composition comprises vitamin C, vitamin A (preferably P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract. It may also be disclosed as the micronutrient and plant extract composition consists of a vitamin C, vitamin A (preferably P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract.
- MSM methyl sulfonylmethane
- the range of physiological dose of the composition depends on mode of delivery. For example oral delivery concentration is different from injection based delivery.
- the vitamin C in the range of 10 mg-20,000 mg, vitamin A (preferably P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg- 3,000mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg- 2,000 mg, zinc in range of lmg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg was calculated as a dosage for mammal.
- Bone ALP is a major regulator of bone mineralization. It hydrolyzes inorganic pyrophosphate, which is a naturally occurring inhibitor of mineralization. Bone ALP also provides inorganic phosphate (from pyrophosphate and organic phosphomonoesters) for the synthesis of hydroxyapatite.
- Core-binding factor alpha 1 (Cbfal) is an essential transcription factor for osteoblastic differentiation and osteogenesis.
- Bone morphogenetic protein (BMP) is also a powerful inducer of differentiation of pluripotent mesenchymal cells to osteoblast lineage and bone formation.
- Skeletal mineralization or bone mineralization relies on a tightly regulated connection between cell activity and extracellular environment.
- researchers in skeletal biology analyze the cellular and molecular events underlying skeletal matrix formation and maintenance, and the mechanisms that promote and limit the mineralization of the matrix.
- Alizarin (1,2- dihydroxyanthraquinone), which emits a red signal under fluorescent green light, has been used for detecting mineralization of osteocytes in in vitro and in vivo labelling for many decades.
- Sclerostin is a small protein expressed by the SOST gene in osteocytes, bone cells that respond to mechanical stress applied to the skeleton and appear to play an important role in the regulation of bone remodeling.
- SOST gene a small protein expressed by the SOST gene in osteocytes, bone cells that respond to mechanical stress applied to the skeleton and appear to play an important role in the regulation of bone remodeling.
- sclerostin binds to its receptors on the cell surface of osteoblasts, a downstream cascade of intracellular signaling is initiated, with the ultimate effect of inhibiting osteoblastic bone formation.
- Horsetail extract (silica), with the purity between 97%-99% according to the manufacturer, were from Monterey Bay Spice (Watsonville, CA). Boron was from Pure Encapsulations (Sudbury, MA). Cells and cell lines were from ATCC (Manassas, VA) or Lonza (Walkersville, MD).
- Cbfa-1 assay Human osteoblasts were plated into 96-well plates at a density of 1 x 10 6 cells/ml per well in a 200 pl volume, and exposed to select micronutrients and plant extracts (0.1-5 pg/ml) for 5 days at 37°C. Afterwards, each well wash washed 3 times with PBS and fixed/ permeabilized with 4% paraformaldehyde/0.1%Triton-X 100 for 1 h at 4°C. In the next step, the cells were washed 3 times with PBS and blocked with 1% BSA followed by incubation with primary antibody against core-binding factor alpha 1 for 2 h at room temperature.
- the cells were washed again 3 times with PBS and incubated with HRP- conjugated secondary antibody against core-binding factor alpha 1 for 2 h at room temperature. Finally, cells were washed 3 times with PBS and TMB peroxidase substrate was added followed by a stop solution and the absorbance was measured at 450 nm within 5 min. using a microplate reader.
- ALP alkaline phosphatase
- Figure 3 shows numbered bars that represent: 1 : Control with 0.05-0.1% DMSO, 2: Control with 0.7 % DMSO, 3: vitamin C, 4: vitamin A (b- carotene), 5: vitamin E, 6: vitamin D3, 7: vitamin K2, 8: folic Acid, 9: calcium, 10: magnesium, 11 : boron, 12: horsetail extract, 13: zinc, 14: potassium, 15: copper, 16: methylsulfonylmethane, 17: stinging nettle extract, 18: Micronutrient and plant extract composition.
- Figure 4 shows results of different ingredients as bars and each bar represents- 1 : Control with 0.05-0.1% DMSO, 2: Control with 0.6 % DMSO, 3: vitamin C, 4: vitamin A (b- Carotene), 5: vitamin E, 6: vitamin D3, 7: vitamin K2, 8: folic Acid, 9: calcium, 10: magnesium, 11 : boron, 12: horsetail extract, 13: zinc, 14: potassium, 15: copper, 16: methylsulfonylmethane, 17: stinging nettle extract and 18: micronutrient and plant extract composition.
- composition according to the present invention shows a significant increase of alkaline phosphatase activity in human osteoblasts.
- the composition according to the present invention shows the highest increase, see entry 17 in Figure 1.
- the reference is entry 1.
- Figure 2 shows the significant increase in core-binding factor al level in human osteoblasts by the ingredients of the composition according to the present invention.
- the reference is entry 2.
- Figure 3 shows the significant increase in mineralization of human osteoblasts by the ingredients of the present composition. The reference again is entry 2.
- Figure 4 shows the significant decrease in sclerostin level in human osteoblasts by the ingredients of the composition of the present invention. From Figure 4 it is evident that the combination of the ingredients in the composition of the present invention shows the largest decrease in sclerostin level, see entry 18 in Figure 4. Therefore, a combination of the ingredients as defined for the composition gives the best effect.
- Drug formulations suitable for these administration routes can be produced by adding one or more pharmacologically acceptable carriers to the composition and then treating the agent and the (micronutrient) composition through a routine process known to those skilled in the art to the composition of vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract.
- the mode of administration includes, but is not limited to, non-invasive peroral, topical (for example, transdermal), enteral, transmucosal, targeted delivery, sustained-release delivery, delayed release, pulsed release and parenteral methods. Peroral administration may be administered both in liquid and dry state.
- (e.g. pharmaceutical micronutrient) composition would be more specifically micronutrient and plant extract composition.
- Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (e.g. using a flavored bases, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin or sucrose and acacia), each containing a predetermined amount of the disclosed composition as an active ingredient.
- Subject compositions may also be administered as a bolus, electuary or paste.
- an oral solid (e.g. drug) product When an oral solid (e.g. drug) product is prepared, the (e.g. pharmaceutical and/or micronutrient) composition is mixed with an excipient (and, if necessary, one or more additives such as a binder, a disintegrant, a lubricant, a coloring agent, a sweetening agent, and a flavoring agent), and the resultant mixture is processed through a routine method, to thereby produce an oral solid (e.g. drug) product such as tablets, coated tablets, granules, powder or capsules.
- Additives may be those generally employed in the art.
- excipients include lactate, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose and silicic acid.
- Binders include water, ethanol, propanol, simple syrup, glucose solution, starch solution, liquefied gelatin, carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl starch, methyl cellulose, ethyl cellulose, shellac, calcium phosphate and polyvinyl pyrrolidone.
- Disintegrants include dried starch, sodium arginate, powdered agar, sodium hydroxy carbonate, calcium carbonate, sodium lauryl sulfate, monoglyceryl stearate and lactose.
- Lubricants include purified talc, stearic acid salts, borax and polyethylene glycol. Sweetening agents include sucrose, orange peel, citric acid and tartaric acid.
- a liquid (e.g. drug) product for oral administration is prepared, the (e.g. pharmaceutical micronutrient) composition is mixed with an additive such as a sweetening agent, a buffer, a stabilizer, or a flavoring agent, and the resultant mixture is processed through a routine method, to produce an orally administered liquid (e.g. drug) product such as an internal solution medicine, syrup or elixir.
- an additive such as a sweetening agent, a buffer, a stabilizer, or a flavoring agent
- the resultant mixture is processed through a routine method, to produce an orally administered liquid (e.g. drug) product such as an internal solution medicine, syrup or elixir.
- the sweetening agent include vanillin
- examples of the buffer include sodium citrate
- examples of the stabilizer include tragacanth, acacia, and gelatin.
- dilute sterile, aqueous or partially aqueous solutions may be prepared with the (e.g. pharmaceutical and/or micronutrient) composition.
- Formulations containing the (e.g. pharmaceutical and/or micronutrient) composition for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating carriers, comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the appropriate body cavity and release the encapsulated compound(s) and composition(s).
- suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the appropriate body cavity and release the encapsulated compound(s) and composition(s).
- suitable non-irritating carriers comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body
- a targeted-release portion for capsules containing the (e.g. pharmaceutical micronutrient) composition can be added to the extended-release system by means of either applying an immediate-release layer on top of the extended release core; using coating or compression processes, or in a multiple-unit system such as a capsule containing extended- and immediate- release beads.
- sustained release When used with respect to a (e.g. pharmaceutical and/or micronutrient) composition, the term “sustained release” is art recognized.
- a therapeutic composition that releases a substance over time may exhibit sustained-release characteristics, in contrast to a bolus type administration in which the entire amount of the substance is made biologically available at one time.
- one or more of the pharmaceutically acceptable excipients may undergo gradual or delayed degradation (e.g., through hydrolysis), with concomitant release of any material incorporated therein, e.g., a therapeutic and/or biologically active salt and/or composition, for a sustained or extended period (as compared with the release from a bolus). This release may result in prolonged delivery of therapeutically effective amounts of any of the therapeutic agents disclosed herein.
- sustained-release formulations in which the (e.g. pharmaceutical and/or micronutrient) composition is released over a period of time in a controlled manner from a formulation.
- sustained release formulations include liposomes, drug-loaded biodegradable microspheres and pharmaceutical micronutrient composition polymer conjugates.
- the delayed-release dosage units can be prepared, for example, by coating a (e.g. pharmaceutical and/or micronutrient) composition with a selected coating material.
- the (e.g. pharmaceutical and/or micronutrient) composition may be a tablet for incorporation into a capsule, a tablet for use as an inner core in a “coated core” dosage form, or a plurality of drug-containing beads, particles or granules, for incorporation into either a tablet or a capsule.
- Preferred coating materials include bioerodible, gradually hydrolysable, gradually water-soluble, and/or enzymatically degradable polymers, and may be conventional “enteric” polymers.
- Enteric polymers become soluble in the higher pH environment of the lower gastrointestinal tract, or slowly erode as the dosage form passes through the gastrointestinal tract, while enzymatically degradable polymers are degraded by bacterial enzymes present in the lower gastrointestinal tract, particularly in the colon.
- a delayed-release tablet may be formulated by dispersing a drug within a matrix of a suitable material such as a hydrophilic polymer or a fatty compound.
- a suitable material such as a hydrophilic polymer or a fatty compound.
- suitable hydrophilic polymers include, but are not limited to, polymers or copolymers of cellulose, cellulose ester, acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate and vinyl or enzymatically degradable polymers or copolymers as described above. These hydrophilic polymers are particularly useful for providing a delayed-release matrix.
- Fatty compounds for use as a matrix material include, but are not limited to, waxes (e.g., carnauba wax) and glycerol tristearate.
- the mixture can be compressed into tablets.
- a pulsed-release dosage is one that mimics a multiple dosing profile without repeated dosing, and typically allows at least a twofold reduction in dosing frequency as compared with the drug presented as a conventional dosage form (e.g., as a solution or prompt drug-releasing, conventional solid dosage form).
- a pulsed-release profile is characterized by a time period of no release (lag time) or reduced release, followed by rapid drug release. These can be formulated for critically ill patients using the instant (e.g. pharmaceutical and/or micronutrient) composition.
- parenteral administration and “administered parenterally” as used herein refer to modes of administration other than enteral and topical, such as injections, and include without limitation intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
- micronutrient composition disclosed herein suitable for parenteral administration, comprise one or more subject compositions in combination with one or more pharmaceutically acceptable sterile, isotonic, aqueous, or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders, which may be reconstituted into sterile injectable solutions or dispersions just prior to use, and which may contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic within the blood of the intended recipient, or suspending or thickening agents.
- the (e.g. pharmaceutical and/or micronutrient) composition is mixed with an additive such as a pH regulator, a buffer, a stabilizer, an isotonicity agent or a local anesthetic, and the resultant mixture is processed through a routine method, to thereby produce an injection for subcutaneous injection, intramuscular injection, or intravenous injection.
- an additive such as a pH regulator, a buffer, a stabilizer, an isotonicity agent or a local anesthetic
- Examples of the pH regulator or buffer include sodium citrate, sodium acetate and sodium phosphate; examples of the stabilizer include sodium pyrosulfite, EDTA, thioglycolic acid, and thiolactic acid; examples of the local anesthetic include procaine hydrochloride and lidocaine hydrochloride; and examples of the isotonicity agent include sodium chloride and glucose.
- Described herein are ready-to-use, premixed (e.g. pharmaceutical and/or micronutrient) compositions of vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg- 1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg or pharmaceutically acceptable salts thereof, which are suitable for continuous intrave
- premixed compositions with a buffered pH
- these (e.g. pharmaceutical and/or micronutrient) compositions are stable at room temperature for at least one year.
- the (pharmaceutical and/or micronutrient) compositions exhibit between 0% to about 15% loss of drug and between 0% to about 3% (w/w) total impurity formation over an eighteen to twenty four month period.
- Additional benefits of the pre-mixed, ready-to-use, injectable e.g.
- compositions include convenience and ease of use as compared to an ampul formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations.
- the present disclosure relates to premixed (e.g.
- compositions comprising vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU- 20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg- 1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methylsulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg or pharmaceutically acceptable salts thereof, one or more tonicity agents, and a buffer.
- the premixed e.g. pharmaceutical and/
- tonicity agents are used to adjust the osmolality of the premixed (e.g. pharmaceutical and/or micronutrient) compositions to bring it closer to the osmotic pressure of body fluids, such as blood or plasma.
- the tonicity of the premixed formulation can be modified by adjusting the concentration of buffer and/or other components present in the premixed formulation.
- Adjuvants are used to enhance the immune response. Various types of adjuvants are available. Haptens and Freund's adjuvant may also be used to produce water-in-oil emulsions of immunogens.
- compositions, polymers and other materials and/or dosage forms that are within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, both human beings and animals, without excessive toxicity, irritation, allergic response or other problem or complication, commensurate with a reasonable benefit-risk ratio.
- pharmaceutically acceptable carrier includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition from one organ or portion of the body, to another organ or portion of the body.
- a pharmaceutically acceptable carrier is non-pyrogenic.
- materials that may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethylene glycol;
- compositions described herein are formulated in a manner such that said compositions will be delivered to a mammal in a therapeutically effective amount, as part of a prophylactic, preventive or therapeutic treatment to overcome the infection caused by corona viruses (irrespective of the type).
- the dosage of the (e.g. pharmaceutical and/or micronutrient) compositions may be determined by reference to the plasma concentrations of the composition or other encapsulated materials.
- the blood samples may be tested for their immune response to their corresponding viral load or lack thereof.
- the (e.g. therapeutic pharmaceutical and/or micronutrient) composition provided by this application may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, topically, parenterally, e.g., intravenously, subcutaneously or intramedullary.
- the therapeutic compositions may be administered intranasally, as a rectal suppository, or using a “flash” formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water.
- the compositions may be administered to a subject in need of treatment by controlled-release dosage forms, site-specific drug delivery, transdermal drug delivery, patch-mediated drug delivery (active/passive), by stereotactic injection, or in nanoparticles.
- an active ingredient can be present in the (therapeutic) compositions of the present invention for localized use via the cutis, intranasally, pharyngolaryngeally, bronchially, intravaginally, rectally or ocularly.
- the active ingredients can be packaged in a pressurized aerosol container together with a gaseous or liquefied propellant, for example dichlorodifluoromethane, carbon dioxide, nitrogen, propane and the like, with the usual adjuvants such as cosolvents and wetting agents, as may be necessary or desirable.
- a gaseous or liquefied propellant for example dichlorodifluoromethane, carbon dioxide, nitrogen, propane and the like
- the usual adjuvants such as cosolvents and wetting agents, as may be necessary or desirable.
- the most common routes of administration also include the preferred transmucosal (nasal, buccal/sublingual, vaginal, ocular and rectal) and inhalation routes.
- the subject (e.g. pharmaceutical and/or micronutrient) composition of the present application may be lyophilized or subjected to another appropriate drying technique such as spray drying.
- the subject compositions may be administered once, or may be divided into a number of smaller doses to be administered at varying intervals of time, depending in part on the release rate of the compositions and the desired dosage.
- Formulations useful in the methods provided herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration a combination thereof.
- the formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy.
- the amount of a subject (e.g. pharmaceutical and/or micronutrient) composition that may be combined with a carrier material to produce a single dose may vary depending upon the subject being treated and the particular mode of administration.
- the therapeutically acceptable amount described herein may be administered in inhalant or aerosol formulations.
- the inhalant or aerosol formulations may comprise one or more agents, such as adjuvants, diagnostic agents, imaging agents, or therapeutic agents useful in inhalation therapy.
- the final aerosol formulation may, for example, contain 0.005-90% w/w, for instance 0.005-50%, 0.005-5% w/w, or 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.
- aqueous and non-aqueous carriers examples include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
- polyols such as glycerol, propylene glycol, polyethylene glycol and the like
- vegetable oils such as olive oil
- injectable organic esters such as ethyl oleate.
- Proper fluidity may be maintained, for example by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
- a micronutrient and plant extract composition comprising: a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract.
- micronutrient and plant extract composition of item 2 wherein the micronutrient and plant extract composition is formulated for treating a mammal to improve bone mineralization.
- micronutrient and plant extract composition of item 3 wherein the mammal is human. 5. The micronutrient and plant extract composition of item 3, wherein the formulation is at least one of an oral, nasal, topical, rectal, vaginal, aerosol, parenteral administration or a combination thereof.
- a method of improving bone mineralization in a mammal comprising; administering a micronutrient and plant extract composition, wherein the micronutrient and plant extract composition is a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract combined at a specific range.
- the micronutrient and plant extract composition is a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract combined at a specific range.
- a method of increasing a bone mineralization comprising; treating a mammal with a need for improving bone health by administering a micronutrient and plant extract composition, wherein the micronutrient and plant extract composition is a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract combined at a specific range.
- the micronutrient and plant extract composition is a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract combined at a specific range.
- the composition consists of vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg- 3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg- 2,000 mg, zinc in range of 1 mg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg.
- the method of iteml 1 wherein the wherein the mammal is human.
Abstract
A composition, comprising: at least 4 vitamins, selected from the group consisting of vitamin C, vitamin A, vitamin E, vitamin D3, vitamin K2, and folic acid; at least 4 minerals, selected from the groups consisting of calcium, magnesium, boron, zinc, potassium, and copper; further comprising methyl sulfonylmethane, horsetail extract, and stinging nettle extract is used for treating, and reversing bone demineralization. The composition when administered to a mammal with or without bone disease strengthens and helps in the bone mineralization process. The composition can be used as a preventive dose for bone demineralization in humans.
Description
COMPOSITION FOR IMPROVING BONE HEALTH
FIELD OF TECHNOLOGY
[001] This application describes a composition containing a micronutrient and plant extract combination and method of using the same for improving bone health.
BACKGROUND
[002] Bone health is very important at every stage in life. Bone mineralization, repair and maintenance is a continuous process and requires good nutrition and exercise to keep it healthy. The body's skeleton forms and grows to its adult size in a process called modeling. It then completely regenerates — or remodels — itself about every 10 years. Remodeling removes old pieces of bone and replaces them with new, fresh bone tissue. This keeps the bone and its cells healthy and strong and allows the bones to supply calcium and other minerals to the body.
[003] Keeping the skeleton in good health requires a balance between removal and replacement of bone tissue. In young, healthy adults, the amount of bone removed and replaced is about the same. This is called balanced bone remodeling. As we age, the remodeling process can shift out of balance, resulting in loss of bone structure and strength, and lead to bone diseases, including osteoporosis.
[004] Maintaining healthy bones requires a continuous supply of nutrients, many of which are not produced in a human body or are available in limited amounts only. These include vitamin C for forming proper collagen, the bone skeleton, which is subsequently hardened by the deposition of minerals. Also, bone building minerals such as calcium, other minerals and trace elements have to originate from dietary sources. Dietary supplementation with one or a few micronutrients does not assure optimum bone metabolism as each component has a different mechanism of action and interaction with other cellular compounds and can lead to metabolic imbalance. This is why there is a need for a selected and experimentally tested composition of essential nutrients that can be applied as a safe and effective measure, such as in a form of a supplement to prevent excessive bone loss and support healthy bone regeneration uniformly through the years.
The object underlying the present invention is to provide a composition that is able to prevent or treat bone diseases, including osteoporosis, and that allows for a balanced bone remodeling in a mammal, preferably human. The composition shall prevent excessive bone loss and shall support healthy bone regeneration uniformly through the years of the live span of a mammal, preferably human.
The object is achieved by a composition, comprising: at least 4 vitamins, selected from the group consisting of vitamin C, vitamin A, vitamin E,
vitamin D3, vitamin K2, and folic acid; at least 4 minerals, selected from the groups consisting of calcium, magnesium, boron, zinc, potassium, and copper; further comprising methylsulfonylmethane, horsetail extract, and stinging nettle extract.
According to the present invention, it has been found that by combining specific micronutrients (vitamins), plant extracts and minerals, a composition can be obtained which improves the bone mineralization of a mammal, preferably human, treated therewith. The composition when taken in by a mammal, preferably human, leads to a balanced bone remodeling and prevents the onset or propagation of bone diseases including osteoporosis. The composition prevents excessive bone loss and supports a healthy bone regeneration uniformly throughout the live span of a mammal, specifically human.
The composition comprises vitamins, (micronutrients), minerals, plant extracts and methylsulfonylmethane.
The composition contains at least four vitamins, preferably at least five vitamins, most preferably all of the above-mentioned vitamins.
Thus, one or two of the above-listed vitamins can be left out in the composition according to the present invention. For the best effect, however, only one vitamin of the above-mentioned list or none of the vitamins of the above-mentioned list is left out.
The metals like calcium, magnesium, boron, zinc, potassium and copper are incorporated in the composition in the form of suitable compounds or salts of the listed elements. Thus, the listed elements stand for salts or compositions or compounds of these elements which are acceptable as a dietary supplement or in pharmaceutical compositions. The listed elements can be considered as minerals since they are typically employed in the form of a mineral containing the element or ion. The composition according to the present invention contains at least four or more, preferably at least five, most preferably all of the minerals listed above. Again, for the best effect, only one or none of the minerals is left out in the composition.
The composition according to the present invention contains horsetail extract and stinging nettle extract, i.e. extracts from equisetum arvense and Urtica dioica. They can be obtained from natural sources by known extraction means. Methyl sulfonylmethane (MSM) is also known as dimethylsulfone. It is a dietary supplement that can be derived from biological sources or be prepared in a chemical synthesis.
The composition, comprising or consisting of the above ingredients as active ingredients can be used to improve bone mineralization, preferably in a mammal, especially human.
In a preferred composition, the ingredients, if present, are present in the following amounts: Vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg- 1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg- 8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg.
Preferably, the composition is formulated for treating a mammal, preferably human, to improve the bone mineralization thereof.
Preferably, the composition comprises only micronutrients (or vitamins), plant extracts and minerals, including methylsulfonylmethane. Therefore, according to one embodiment of the invention, the composition consists of the vitamins, plant extracts, minerals and methyl sulfonylmethane as active ingredients and allows only for the presence of a carrier material, which is acceptable in dietary supplements and pharmaceutical compositions.
A preferred composition consists of the above listed ingredients.
Preferably, the composition is formulated for oral, nasal, topical, rectal, vaginal, aerosol and/or parenteral administration.
Preferred embodiments of the invention are as follows:
1. In the composition at least five vitamins, selected from the group consisting of vitamin C, vitamin A, vitamin E, vitamin D3, vitamin K2 and folic acid are present and/or at least five minerals, selected from the group consisting of calcium, magnesium, boron, zinc, potassium and copper are present in the composition.
2. The composition comprises or consists of vitamin C, vitamin A, Vitamin E, Vitamin D3, Vitamin K2, folic acid, calcium, magnesium, boron, zinc, potassium, copper, methyl sulfonylmethane, horsetail extract and stinging nettle extract.
3. The use of the composition as a dietary supplement.
4. A dietary supplement, comprising a composition as defined above.
5. A pharmaceutical composition, comprising the composition as defined above, and optionally, a pharmaceutically acceptable carrier
6. The pharmaceutical composition for use in the treatment of osteoporosis.
7. A process for preparing the composition, the dietary supplement or the pharmaceutical composition as defined above, comprising the step of mixing the ingredients thereof and optionally formulating the mixture for oral, nasal, topical, rectal, vaginal, aerosol and/or parenteral administration.
8. The use of a composition or dietary supplement as defined above for improving the bone mineralization in a mammal.
The invention also relates to a method of improving bone mineralization, preferably in a mammal, comprising: administering a composition, a dietary supplement or a pharmaceutical composition as outlined above.
Preferred is a method as defined above, further comprising decreasing a sclerostin level in a human osteoblasts treated with the said composition to improve bone health, and/or further comprising increasing a core-binding factor alpha 1 level in human osteoblasts treated with the said composition to improve bone mineralization, and/or further comprising increasing a level of alkaline phosphatase activity in human osteoblasts by treating with the said composition to improve bone mineralization.
In the following, the preferred composition is described which comprises all of the above-listed vitamins, minerals, plant extracts and methyl sulfonyl methane. The effects and ranges also relate to the subset of the ingredients as outlined above.
In the following, the composition is also described as a micronutrient and plant extract composition, which is intended to encompass the micronutrients or vitamins, plant extracts and minerals and methyl sulfonylmethane as outlined above for the composition.
SUMMARY
[005] In the instant disclosure various combinations of micronutrient and plant extract as a composition were used to treat, prevent, support, improve and enhance bone health. In one embodiment a physiological dose for a mammal was calculated based on daily consumption. The micronutrient and plant extract composition was packaged in drug formulation for easy consumption by mammals. The physiological calculations were based on in-vitro experiments and mode of delivery for consumption by human.
[006] In one embodiment, the (micronutrient and plant extract) composition comprises of a vitamin C, vitamin A (preferably P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, zinc, potassium, copper, methyl sulfonylmethane (MSM), horsetail extract, and stinging nettle extract.
[007] In another embodiment, the concentration of each ingredient in the (micronutrient and plant extract) composition are vitamin C in the range of 10 mg-20,000 mg, vitamin A
(preferably P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of lmg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000mg and stinging nettle extract in range of 10 mg- 5,000 mg.
[008] In one embodiment, a method of increasing bone mineralization by increasing alkaline phosphatase enzyme activity, core-binding factor alpha (1) transcription factor in mineralization of human osteoblasts and reducing sclerostin enzyme activity by administering the (micronutrient and plant extract) composition.
[009] In one embodiment, a method of increasing bone mineralization by increasing the alkaline phosphate activity in human osteoblast cells using the (micronutrient and plant extract) composition containing a combination of vitamin C in the range of 10 mg-20,000 mg, vitamin A (preferably P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of lmg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000mg and stinging nettle extract in range of 10 mg- 5,000 mg is disclosed.
[010] In one embodiment, a method of increasing bone mineralization by increasing the alkaline phosphate activity in human osteoblast cells using the (micronutrient and plant extract) composition containing a combination of vitamin C in the range of 10 mg-20,000 mg, vitamin A (preferably P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of lmg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000mg and stinging nettle extract in range of 10 mg- 5,000 mg.
[OH] In one embodiment, a method of administering the (micronutrient and plant extract) composition as a drug formulation suitable for increasing bone mineralization in mammal containing a combination of vitamin C in the range of 10 mg-20,000 mg, vitamin A (preferably P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of lmg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg,
methyl sulfonylmethane in range of 10 mg-8,000mg and stinging nettle extract in range of 10 mg- 5,000 mg are disclosed.
BRIEF DESCRIPTION OF DRAWINGS
[012] Example embodiments are illustrated by way of example and not limitation in the figures of the accompanying drawings, in which like references indicate similar elements and in which: [013] Figure 1 shows Alkaline phosphatase (ALP) activity in human osteoblasts after exposure to selected micronutrients and plant extracts.
[014] Figure 2 shows core-binding factor alpha 1 (Cbfa-1) detection in human osteoblasts after treatment with different micronutrients and plant extracts.
[015] Figure 3 shows mineralization level of human osteoblasts stimulated by different micronutrients and plant extracts.
[016] Figure 4 shows Sclerostin detection in human osteoblasts after treatment with different micronutrients and plant extracts.
[017] Others features of the present embodiments will be apparent from the accompanying drawings and from the detailed description that follows.
DETAILED DESCRIPTION
[018] In the instant disclosure the (micronutrient and plant extract) composition comprises vitamin C, vitamin A (preferably P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract. It may also be disclosed as the micronutrient and plant extract composition consists of a vitamin C, vitamin A (preferably P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract. The range of physiological dose of the composition depends on mode of delivery. For example oral delivery concentration is different from injection based delivery. Hence the vitamin C in the range of 10 mg-20,000 mg, vitamin A (preferably P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg- 3,000mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg- 2,000 mg, zinc in range of lmg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg was calculated as a dosage for mammal. The disclosed micronutrient and plant extract composition are used to treat human that are in need of bone remineralization and improve bone density and bone strength. The instant composition works at three different levels that are described below.
[019] Bone ALP is a major regulator of bone mineralization. It hydrolyzes inorganic pyrophosphate, which is a naturally occurring inhibitor of mineralization. Bone ALP also
provides inorganic phosphate (from pyrophosphate and organic phosphomonoesters) for the synthesis of hydroxyapatite.
[020] Core-binding factor alpha 1 (Cbfal) is an essential transcription factor for osteoblastic differentiation and osteogenesis. Bone morphogenetic protein (BMP) is also a powerful inducer of differentiation of pluripotent mesenchymal cells to osteoblast lineage and bone formation. [021] Skeletal mineralization or bone mineralization relies on a tightly regulated connection between cell activity and extracellular environment. Researchers in skeletal biology analyze the cellular and molecular events underlying skeletal matrix formation and maintenance, and the mechanisms that promote and limit the mineralization of the matrix. Alizarin (1,2- dihydroxyanthraquinone), which emits a red signal under fluorescent green light, has been used for detecting mineralization of osteocytes in in vitro and in vivo labelling for many decades.
[022] Sclerostin is a small protein expressed by the SOST gene in osteocytes, bone cells that respond to mechanical stress applied to the skeleton and appear to play an important role in the regulation of bone remodeling. When sclerostin binds to its receptors on the cell surface of osteoblasts, a downstream cascade of intracellular signaling is initiated, with the ultimate effect of inhibiting osteoblastic bone formation.
[023] Materials and Methods: The experiments are conducted in-vitro and the (micronutrient and plant extract) composition are tested individually and in combination in several assays to show the efficacy and preventive nature of the said composition in treating bone demineralization. The following compounds, with the purity between 90%-98% according to the manufacturer, were obtained from Sigma (St. Louis, MO): vitamin A, vitamin C, vitamins D3, and folic acid. The compounds such as vitamin E, vitamin K2, zinc, magnesium, calcium, copper, potassium, MSM, and nettle extract, with the purity between 90%-98% according to the manufacturer, were purchased from Powder City (York, PA). Horsetail extract (silica), with the purity between 97%-99% according to the manufacturer, were from Monterey Bay Spice (Watsonville, CA). Boron was from Pure Encapsulations (Sudbury, MA). Cells and cell lines were from ATCC (Manassas, VA) or Lonza (Walkersville, MD).
[024] The following assays were performed according to manufactures’ protocols. In vitro differentiation (alkaline phosphatase activity (ALP) and core-binding factor alpha 1 (Cbfa-1) as a marker) assay: Human osteoblasts (1 x 105 cells/well of a 96-well plate) in a 100 pl cell culture medium were exposed to select micronutrients and plant extracts (0.1-5 pg/ml) for 48 h at 37°C, and lysed with assay buffer. Subsequently, 5 mM p-nitrophenyl phosphate (pNPP), as a phosphate substrate for alkaline phosphates, was added into all experimental wells for 1 h, followed by a stop solution. The absorbance was measured at 450 nm within 5 min. using a microplate reader.
[025] Cbfa-1 assay: Human osteoblasts were plated into 96-well plates at a density of 1 x 106 cells/ml per well in a 200 pl volume, and exposed to select micronutrients and plant extracts (0.1-5 pg/ml) for 5 days at 37°C. Afterwards, each well wash washed 3 times with PBS and fixed/ permeabilized with 4% paraformaldehyde/0.1%Triton-X 100 for 1 h at 4°C. In the next
step, the cells were washed 3 times with PBS and blocked with 1% BSA followed by incubation with primary antibody against core-binding factor alpha 1 for 2 h at room temperature. Than cells were washed again 3 times with PBS and incubated with HRP-conjugated secondary antibody against core-binding factor alpha 1 for 2 h at room temperature. Finally, cells were washed 3 times with PBS and TMB peroxidase substrate was added followed by a stop solution and the absorbance was measured at 450 nm within 5 min. using a microplate reader.
[026] In vitro mineralization assay: Human osteoblasts were plated into 96-well plates at a density of 1 x 106 cells/ml per well in a 150 pl volume, and exposed every fourth day to fresh additions of select micronutrients and plant extracts (5-20 pg/ml) for a total period of 3 weeks at 37°C. Afterwards, each well wash washed 3 times with PBS and alizarin red S (100 pl) was added to each well for 45 min followed again by three washes with distilled water. Next 100 pl of PBS was added to all wells and the absorbance was measured at 405 nm within 5 min. using a microplate reader.
[027] In vitro bone matrix resorption (sclerostin as a marker) assay: Human osteoblasts were plated into 96-well plates at a density of 1 x 106 cells/ml per well in a 200 pl volume, and exposed to select micronutrients and plant extracts (0.1-5 pg/ml) for 2 weeks at 37°C. Subsequently, each well was washed 3 times with PBS and fixed/ permeabilized with 4% paraformaldehyde/0.1%Triton-X 100 for 1 h at 4°C. Next cells were washed 3 times with PBS and blocked with 1% BSA followed by incubation with primary antibody against sclerostin for 2 h at room temperature. The cells were washed again 3 times with PBS and incubated with HRP- conjugated secondary antibody against core-binding factor alpha 1 for 2 h at room temperature. Finally, cells were washed 3 times with PBS and TMB peroxidase substrate was added followed by a stop solution and the absorbance was measured at 450 nm within 5 min. using a microplate reader.
[028] Statistical analysis: Means and standard deviations were determined for all experiments and Student's t test analysis was applied to determine statistically significant differences. Statistical analysis was performed by two-sample paired t-test using GraphPad statistical software.
[029] Figure 1 shows alkaline phosphatase (ALP) activity level in human osteoblasts after exposure to selected micronutrients and plant extracts (0.1-5 pg/ml) for 48 h at 37 °C and expressed as the mean ± standard deviation (n = 4). Value significantly different from corresponding control at * p<0.05, ** p<0.01, *** p<0.001, + p<0.05 compared to the most stimulating agents (boron and MSM), respectively. Statistically significant increase of alkaline phosphatase activity in human osteoblasts treated with the composition of 15 (comprising vitamins, minerals and plant extracts) was observed when compared to the control (line 1) and to the most stimulating agents (i.e., boron line 10 and MSM line 15 respectively). The bar numbers in figure 1 is described as follows: 1- control; 2- vitamin C;3-vitamin A (beta carotene);4- vitamin E; 5-vitamin D3; 6-vitamin k2; 7- folic acid;8-calcium; 9-magnesium; 10-boron; 11-
horsetail extract; 12-zinc; 13-potassium; 14-copper; 15- MSM; 16-stinging nettle extract, 17-Mix of ingredients 15 ingredients (2-16).
[030] Figure 2 shows the effects of selected micronutrients and plant extracts (0.1-5 pg/ml) on core-binding factor alpha 1 (Cbfa-1) detection in human osteoblasts after treatment for 5 days at 37 °C. The results are expressed as the mean ± standard deviation (n = 4). Due to different final concentrations of DMSO in individual samples and the mix, two controls were applied: 0.05- 0.1% DMSO and 0.6% DMSO. Value significantly different from control with 0.05-0.1% DMSO (*) p<0.05, from control with 0.6% DMSO (+) p<0.05. Statistically significant increase in core-binding factor alpha 1 level in human osteoblasts treated with the composition of vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methylsulfonylmethane (MSM) and stinging nettle extract was observed when compared to the corresponding control (0.6% DMSO). The figure shows numbered bars and they represent: 1. control with 0.05-0.1% DMSO, 2: Control with 0.6 % DMSO, 3: vitamin C, 4: vitamin A (b-Carotene), 5: vitamin E, 6: vitamin D3, 7: vitamin K2, 8: folic Acid, 9: calcium, 10: magnesium, 11 : boron, 12: horsetail extract, 13: zinc, 14: potassium, 15: copper, 16: MSM, 17: stinging nettle extract and 18: micronutrient and plant extract composition.
[031] Figure 3 shows changes in the mineralization level of human osteoblasts in the presence of selected micronutrients and plant extracts (0.1-5 pg/ml) after exposure for 3 weeks at 37 °C. Mineralization was assessed by the alizarin red S staining method and expressed as the mean ± standard deviation (n = 4). Value significantly different from corresponding control (i.e., with 0.7% DMSO) at ** p<0.01. Statistically significant increase in mineralization of human osteoblasts was observed with the combination of vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract when compared to the corresponding control (0.7% DMSO). Figure 3 shows numbered bars that represent: 1 : Control with 0.05-0.1% DMSO, 2: Control with 0.7 % DMSO, 3: vitamin C, 4: vitamin A (b- carotene), 5: vitamin E, 6: vitamin D3, 7: vitamin K2, 8: folic Acid, 9: calcium, 10: magnesium, 11 : boron, 12: horsetail extract, 13: zinc, 14: potassium, 15: copper, 16: methylsulfonylmethane, 17: stinging nettle extract, 18: Micronutrient and plant extract composition.
[032] Figure 4 shows changes in Sclerostin levels in human osteoblasts after their treatment with selected micronutrients and plant extracts (0.1-5 pg/ml) for 2 weeks at 37 °C. The results are expressed as the mean ± standard deviation (n = 3). Value significantly different from control with 0.05-0.1% DMSO (*) p<0.05-0.01, from control with 0.6% DMSO (+) p<0.05. Statistically significant decrease in sclerostin level in human osteoblasts treated with the composition of vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract was observed when compared to the corresponding control (with 0.6% DMSO). Figure 4 shows results of different ingredients as bars and each bar represents- 1 :
Control with 0.05-0.1% DMSO, 2: Control with 0.6 % DMSO, 3: vitamin C, 4: vitamin A (b- Carotene), 5: vitamin E, 6: vitamin D3, 7: vitamin K2, 8: folic Acid, 9: calcium, 10: magnesium, 11 : boron, 12: horsetail extract, 13: zinc, 14: potassium, 15: copper, 16: methylsulfonylmethane, 17: stinging nettle extract and 18: micronutrient and plant extract composition.
As it is evident from Figure 1, all ingredients of the composition according to the present invention show a significant increase of alkaline phosphatase activity in human osteoblasts. The composition according to the present invention shows the highest increase, see entry 17 in Figure 1. The reference is entry 1.
Figure 2 shows the significant increase in core-binding factor al level in human osteoblasts by the ingredients of the composition according to the present invention. Here, the reference is entry 2.
Figure 3 shows the significant increase in mineralization of human osteoblasts by the ingredients of the present composition. The reference again is entry 2.
Figure 4 shows the significant decrease in sclerostin level in human osteoblasts by the ingredients of the composition of the present invention. From Figure 4 it is evident that the combination of the ingredients in the composition of the present invention shows the largest decrease in sclerostin level, see entry 18 in Figure 4. Therefore, a combination of the ingredients as defined for the composition gives the best effect.
[033] Drug formulations suitable for these administration routes can be produced by adding one or more pharmacologically acceptable carriers to the composition and then treating the agent and the (micronutrient) composition through a routine process known to those skilled in the art to the composition of vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane (MSM) and stinging nettle extract. The mode of administration includes, but is not limited to, non-invasive peroral, topical (for example, transdermal), enteral, transmucosal, targeted delivery, sustained-release delivery, delayed release, pulsed release and parenteral methods. Peroral administration may be administered both in liquid and dry state. In one embodiment, (e.g. pharmaceutical micronutrient) composition would be more specifically micronutrient and plant extract composition.
[034] Formulations suitable for oral administration may be in the form of capsules, cachets, pills, tablets, lozenges (e.g. using a flavored bases, usually sucrose and acacia or tragacanth), powders, granules, or as a solution or a suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil liquid emulsion, or as an elixir or syrup, or as pastilles (using an inert base, such as gelatin and glycerin or sucrose and acacia), each containing a predetermined amount of the disclosed composition as an active ingredient. Subject compositions may also be administered as a bolus, electuary or paste.
[035] When an oral solid (e.g. drug) product is prepared, the (e.g. pharmaceutical and/or micronutrient) composition is mixed with an excipient (and, if necessary, one or more additives such as a binder, a disintegrant, a lubricant, a coloring agent, a sweetening agent, and a flavoring
agent), and the resultant mixture is processed through a routine method, to thereby produce an oral solid (e.g. drug) product such as tablets, coated tablets, granules, powder or capsules. Additives may be those generally employed in the art. Examples of excipients include lactate, sucrose, sodium chloride, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose and silicic acid. Binders include water, ethanol, propanol, simple syrup, glucose solution, starch solution, liquefied gelatin, carboxymethylcellulose, hydroxypropyl cellulose, hydroxypropyl starch, methyl cellulose, ethyl cellulose, shellac, calcium phosphate and polyvinyl pyrrolidone. Disintegrants include dried starch, sodium arginate, powdered agar, sodium hydroxy carbonate, calcium carbonate, sodium lauryl sulfate, monoglyceryl stearate and lactose. Lubricants include purified talc, stearic acid salts, borax and polyethylene glycol. Sweetening agents include sucrose, orange peel, citric acid and tartaric acid.
[036] When a liquid (e.g. drug) product for oral administration is prepared, the (e.g. pharmaceutical micronutrient) composition is mixed with an additive such as a sweetening agent, a buffer, a stabilizer, or a flavoring agent, and the resultant mixture is processed through a routine method, to produce an orally administered liquid (e.g. drug) product such as an internal solution medicine, syrup or elixir. Examples of the sweetening agent include vanillin; examples of the buffer include sodium citrate; and examples of the stabilizer include tragacanth, acacia, and gelatin.
[037] For the purposes of transdermal (e.g., topical) administration, dilute sterile, aqueous or partially aqueous solutions (usually in about 0.1% to 5% concentration), otherwise similar to the above parenteral solutions, may be prepared with the (e.g. pharmaceutical and/or micronutrient) composition.
[038] Formulations containing the (e.g. pharmaceutical and/or micronutrient) composition for rectal or vaginal administration may be presented as a suppository, which may be prepared by mixing a subject composition with one or more suitable non-irritating carriers, comprising, for example, cocoa butter, polyethylene glycol, a suppository wax or a salicylate, which is solid at room temperature, but liquid at body temperature and, therefore, will melt in the appropriate body cavity and release the encapsulated compound(s) and composition(s). Formulations that are suitable for vaginal administration also include pessaries, tampons, creams, gels, pastes, foams or spray formulations containing such carriers as are known in the art to be appropriate.
[039] A targeted-release portion for capsules containing the (e.g. pharmaceutical micronutrient) composition can be added to the extended-release system by means of either applying an immediate-release layer on top of the extended release core; using coating or compression processes, or in a multiple-unit system such as a capsule containing extended- and immediate- release beads.
[040] When used with respect to a (e.g. pharmaceutical and/or micronutrient) composition, the term “sustained release” is art recognized. For example, a therapeutic composition that releases a substance over time may exhibit sustained-release characteristics, in contrast to a bolus type administration in which the entire amount of the substance is made biologically available at one
time. In particular embodiments, upon contact with body fluids, including blood, spinal fluid, mucus secretions, lymph or the like, one or more of the pharmaceutically acceptable excipients may undergo gradual or delayed degradation (e.g., through hydrolysis), with concomitant release of any material incorporated therein, e.g., a therapeutic and/or biologically active salt and/or composition, for a sustained or extended period (as compared with the release from a bolus). This release may result in prolonged delivery of therapeutically effective amounts of any of the therapeutic agents disclosed herein.
[041] Current efforts in the area of drug delivery include the development of targeted delivery, in which the drug is only active in the target area of the body (for example, mucous membranes such as in the nasal cavity), and sustained-release formulations, in which the (e.g. pharmaceutical and/or micronutrient) composition is released over a period of time in a controlled manner from a formulation. Types of sustained release formulations include liposomes, drug-loaded biodegradable microspheres and pharmaceutical micronutrient composition polymer conjugates. [042] Delayed-release dosage formulations are created by coating a solid dosage form with a film of a polymer, which is insoluble in the acid environment of the stomach, but soluble in the neutral environment of the small intestine. The delayed-release dosage units can be prepared, for example, by coating a (e.g. pharmaceutical and/or micronutrient) composition with a selected coating material. The (e.g. pharmaceutical and/or micronutrient) composition may be a tablet for incorporation into a capsule, a tablet for use as an inner core in a “coated core” dosage form, or a plurality of drug-containing beads, particles or granules, for incorporation into either a tablet or a capsule. Preferred coating materials include bioerodible, gradually hydrolysable, gradually water-soluble, and/or enzymatically degradable polymers, and may be conventional “enteric” polymers. Enteric polymers, as will be appreciated by those skilled in the art, become soluble in the higher pH environment of the lower gastrointestinal tract, or slowly erode as the dosage form passes through the gastrointestinal tract, while enzymatically degradable polymers are degraded by bacterial enzymes present in the lower gastrointestinal tract, particularly in the colon.
Alternatively, a delayed-release tablet may be formulated by dispersing a drug within a matrix of a suitable material such as a hydrophilic polymer or a fatty compound. Suitable hydrophilic polymers include, but are not limited to, polymers or copolymers of cellulose, cellulose ester, acrylic acid, methacrylic acid, methyl acrylate, ethyl acrylate and vinyl or enzymatically degradable polymers or copolymers as described above. These hydrophilic polymers are particularly useful for providing a delayed-release matrix. Fatty compounds for use as a matrix material include, but are not limited to, waxes (e.g., carnauba wax) and glycerol tristearate.
Once the active ingredient is mixed with the matrix material, the mixture can be compressed into tablets.
[043] A pulsed-release dosage is one that mimics a multiple dosing profile without repeated dosing, and typically allows at least a twofold reduction in dosing frequency as compared with the drug presented as a conventional dosage form (e.g., as a solution or prompt drug-releasing, conventional solid dosage form). A pulsed-release profile is characterized by a time period of no
release (lag time) or reduced release, followed by rapid drug release. These can be formulated for critically ill patients using the instant (e.g. pharmaceutical and/or micronutrient) composition. [044] The phrases “parenteral administration” and “administered parenterally” as used herein refer to modes of administration other than enteral and topical, such as injections, and include without limitation intravenous, intramuscular, intrapleural, intravascular, intrapericardial, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular, subarachnoid, intraspinal and intrastemal injection and infusion.
[045] The micronutrient composition disclosed herein, suitable for parenteral administration, comprise one or more subject compositions in combination with one or more pharmaceutically acceptable sterile, isotonic, aqueous, or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders, which may be reconstituted into sterile injectable solutions or dispersions just prior to use, and which may contain antioxidants, buffers, bacteriostats, solutes that render the formulation isotonic within the blood of the intended recipient, or suspending or thickening agents.
[046] When an injection product is prepared, the (e.g. pharmaceutical and/or micronutrient) composition is mixed with an additive such as a pH regulator, a buffer, a stabilizer, an isotonicity agent or a local anesthetic, and the resultant mixture is processed through a routine method, to thereby produce an injection for subcutaneous injection, intramuscular injection, or intravenous injection. Examples of the pH regulator or buffer include sodium citrate, sodium acetate and sodium phosphate; examples of the stabilizer include sodium pyrosulfite, EDTA, thioglycolic acid, and thiolactic acid; examples of the local anesthetic include procaine hydrochloride and lidocaine hydrochloride; and examples of the isotonicity agent include sodium chloride and glucose.
[047] Described herein are ready-to-use, premixed (e.g. pharmaceutical and/or micronutrient) compositions of vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg- 1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg or pharmaceutically acceptable salts thereof, which are suitable for continuous intravenous infusion. By providing ready-to-use, premixed (e.g. pharmaceutical and/or micronutrient) compositions with a buffered pH, these (e.g. pharmaceutical and/or micronutrient) compositions are stable at room temperature for at least one year. When stored at room temperature, the (pharmaceutical and/or micronutrient) compositions exhibit between 0% to about 15% loss of drug and between 0% to about 3% (w/w) total impurity formation over an eighteen to twenty four month period.
[048] Additional benefits of the pre-mixed, ready-to-use, injectable (e.g. pharmaceutical and/or micronutrient) compositions include convenience and ease of use as compared to an ampul formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations. The present disclosure relates to premixed (e.g. pharmaceutical and/or micronutrient) compositions comprising vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU- 20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg- 1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methylsulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg or pharmaceutically acceptable salts thereof, one or more tonicity agents, and a buffer. In some embodiments, the premixed (e.g. pharmaceutical and/or micronutrient) compositions further comprise one or more tonicity agents.
[049] Typically, tonicity agents are used to adjust the osmolality of the premixed (e.g. pharmaceutical and/or micronutrient) compositions to bring it closer to the osmotic pressure of body fluids, such as blood or plasma. In some embodiments the tonicity of the premixed formulation can be modified by adjusting the concentration of buffer and/or other components present in the premixed formulation. Adjuvants are used to enhance the immune response. Various types of adjuvants are available. Haptens and Freund's adjuvant may also be used to produce water-in-oil emulsions of immunogens.
[050] The phrase “pharmaceutically acceptable” is art recognized. In certain embodiments, the term includes compositions, polymers and other materials and/or dosage forms that are within the scope of sound medical judgment, suitable for use in contact with the tissues of mammals, both human beings and animals, without excessive toxicity, irritation, allergic response or other problem or complication, commensurate with a reasonable benefit-risk ratio. [051] The phrase “pharmaceutically acceptable carrier” is art recognized, and includes, for example, pharmaceutically acceptable materials, compositions or vehicles, such as a liquid or solid filler, diluent, solvent or encapsulating material involved in carrying or transporting any subject composition from one organ or portion of the body, to another organ or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of a subject composition, and not injurious to the patient. In certain embodiments, a pharmaceutically acceptable carrier is non-pyrogenic. Some examples of materials that may serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, com oil and soybean oil; (10)
glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffering agents, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen- free water; (17) isotonic saline; (18) Ringer’s solution; (19) ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxic compatible substances employed in pharmaceutical formulations.
[052] In certain embodiments, the (e.g. pharmaceutical and/or micronutrient) compositions described herein are formulated in a manner such that said compositions will be delivered to a mammal in a therapeutically effective amount, as part of a prophylactic, preventive or therapeutic treatment to overcome the infection caused by corona viruses (irrespective of the type).
[053] In certain embodiments, the dosage of the (e.g. pharmaceutical and/or micronutrient) compositions, which may be referred to as therapeutic composition provided herein, may be determined by reference to the plasma concentrations of the composition or other encapsulated materials. For example, the blood samples may be tested for their immune response to their corresponding viral load or lack thereof.
[054] The (e.g. therapeutic pharmaceutical and/or micronutrient) composition provided by this application may be administered to a subject in need of treatment by a variety of conventional routes of administration, including orally, topically, parenterally, e.g., intravenously, subcutaneously or intramedullary. Further, the therapeutic compositions may be administered intranasally, as a rectal suppository, or using a “flash” formulation, i.e., allowing the medication to dissolve in the mouth without the need to use water. Furthermore, the compositions may be administered to a subject in need of treatment by controlled-release dosage forms, site-specific drug delivery, transdermal drug delivery, patch-mediated drug delivery (active/passive), by stereotactic injection, or in nanoparticles.
[055] Expressed in terms of concentration, an active ingredient can be present in the (therapeutic) compositions of the present invention for localized use via the cutis, intranasally, pharyngolaryngeally, bronchially, intravaginally, rectally or ocularly.
[056] For use as aerosols, the active ingredients can be packaged in a pressurized aerosol container together with a gaseous or liquefied propellant, for example dichlorodifluoromethane, carbon dioxide, nitrogen, propane and the like, with the usual adjuvants such as cosolvents and wetting agents, as may be necessary or desirable. The most common routes of administration also include the preferred transmucosal (nasal, buccal/sublingual, vaginal, ocular and rectal) and inhalation routes.
[057] In addition, in certain embodiments, the subject (e.g. pharmaceutical and/or micronutrient) composition of the present application may be lyophilized or subjected to another appropriate drying technique such as spray drying. The subject compositions may be administered once, or may be divided into a number of smaller doses to be administered at
varying intervals of time, depending in part on the release rate of the compositions and the desired dosage.
[058] Formulations useful in the methods provided herein include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal, aerosol and/or parenteral administration a combination thereof. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. The amount of a subject (e.g. pharmaceutical and/or micronutrient) composition that may be combined with a carrier material to produce a single dose may vary depending upon the subject being treated and the particular mode of administration.
[059] The therapeutically acceptable amount described herein may be administered in inhalant or aerosol formulations. The inhalant or aerosol formulations may comprise one or more agents, such as adjuvants, diagnostic agents, imaging agents, or therapeutic agents useful in inhalation therapy. The final aerosol formulation may, for example, contain 0.005-90% w/w, for instance 0.005-50%, 0.005-5% w/w, or 0.01-1.0% w/w, of medicament relative to the total weight of the formulation.
[060] Examples of suitable aqueous and non-aqueous carriers that may be employed in the pharmaceutical micronutrient composition include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol and the like), and suitable mixtures thereof, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Proper fluidity may be maintained, for example by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
In the following, different items of the invention are described:
1. A micronutrient and plant extract composition, comprising: a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract.
2. The micronutrient and plant extract composition of item 1, wherein the vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg- 45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg.
3. The micronutrient and plant extract composition of item 2, wherein the micronutrient and plant extract composition is formulated for treating a mammal to improve bone mineralization.
4. The micronutrient and plant extract composition of item 3, wherein the mammal is human.
5. The micronutrient and plant extract composition of item 3, wherein the formulation is at least one of an oral, nasal, topical, rectal, vaginal, aerosol, parenteral administration or a combination thereof.
6. A method of improving bone mineralization in a mammal, comprising; administering a micronutrient and plant extract composition, wherein the micronutrient and plant extract composition is a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract combined at a specific range.
7. The method of item 6, wherein the specific range is vitamin C in the range of 10 mg- 20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg-2,000 mg, zinc in range of 1 mg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg.
8. The method of item 7, further comprising; decreasing a sclerostin level in a human osteoblasts treated with the said composition to improve bone health.
9. The method of item 7, further comprising; increasing a core-binding factor alpha 1 level in human osteoblasts treated with the said composition to improve bone mineralization.
10. The method of item 7, further comprising; increasing a level of alkaline phosphatase activity in human osteoblasts by treating with the said composition to improve bone mineralization.
11. A method of increasing a bone mineralization, comprising; treating a mammal with a need for improving bone health by administering a micronutrient and plant extract composition, wherein the micronutrient and plant extract composition is a vitamin C, vitamin A (P-carotene), vitamin E, vitamin D3, vitamin K2, folic acid, calcium, magnesium, boron, horsetail extract, zinc, potassium, copper, methyl sulfonylmethane and stinging nettle extract combined at a specific range.
12. The method of item 11, wherein the composition consists of vitamin C in the range of 10 mg-20,000 mg, vitamin A (P-carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg- 3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg- 2,000 mg, zinc in range of 1 mg-1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg.
13. The method of iteml 1, wherein the wherein the mammal is human.
14. The method of item 12, further comprising; formulating the micronutrient and plant extract composition for human consumption.
15. The method of item 14, wherein the formulation is at least one of an oral, nasal, topical, rectal, vaginal, aerosol, parenteral administration or a combination thereof.
Claims
1. A composition, comprising: at least 4 vitamins, selected from the group consisting of vitamin C, vitamin A, vitamin E, vitamin D3, vitamin K2, and folic acid; at least 4 minerals, selected from the groups consisting of calcium, magnesium, boron, zinc, potassium, and copper; further comprising methyl sulfonylmethane, horsetail extract, and stinging nettle extract.
2. The composition of claim 1, wherein the ingredients, if present, are present in the following amounts: the vitamin C in the range of 10 mg-20,000 mg, vitamin A (P- carotene) in range of 5 mg-400 mg, vitamin E in range of 10 mg-3,000 mg, vitamin D3 in range of 10 IU-20,000 IU, vitamin K2 in range of 20 mcg-45,000 mcg, folic acid in range of 10 mcg-2,000 mcg, calcium in range of 10 mg-5,000 mg, magnesium in range of 10 mg-5,000 mg, boron in range of 1 mg-70 mg, horsetail extract in range of 10 mg- 2,000 mg, zinc in range of 1 mg- 1,000 mg, potassium in range of 10 mg-3,500 mg, copper in range of 0.1 mg-50 mg, methyl sulfonylmethane in range of 10 mg-8,000 mg and stinging nettle extract in range of 10 mg-5,000 mg.
3. The composition of claim 1 or 2, wherein the composition is formulated for treating a mammal, preferably human, to improve the bone mineralization thereof.
4. The composition of one of claims 1 to 3, wherein the composition comprises only micronutrients or vitamins, plant extracts and minerals.
5. The composition of one of claims 1 to 4, wherein the composition is formulated for oral, nasal, topical, rectal, vaginal, aerosol and/or parenteral administration.
6. The composition of one of claims 1 to 5, wherein at least five vitamins, selected from the group consisting of vitamin C, vitamin A, vitamin E, vitamin D3, vitamin K2 and folic acid are present and/or wherein at least five minerals, selected from the group consisting of calcium, magnesium, boron, zinc, potassium and copper are present in the composition.
7. The composition of claim 6, wherein the composition comprises or consists of vitamin C, vitamin A, Vitamin E, Vitamin D3, Vitamin K2, folic acid, calcium, magnesium, boron, zinc, potassium, copper, methyl sulfonylmethane, horsetail extract and stinging nettle extract.
8. A use of the composition of one of claims 1 to 7 as a nutritional supplement.
9. Nutritional supplement, comprising a composition as claimed in one of claims 1 to 7.
10. A pharmaceutical composition, comprising the composition as claimed in one of claims 1 to 7, and optionally, a pharmaceutically acceptable carrier
11. The pharmaceutical composition of claim 10 for use in the treatment of osteoporosis.
A process for preparing the composition of one of claims 1 to 7, the nutritional supplement of claim 9 or the pharmaceutical composition according to claim 10 or 11, comprising the step of mixing the ingredients thereof and optionally formulating the mixture for oral, nasal, topical, rectal, vaginal, aerosol and/or parenteral administration. The use of a composition of one of claims 1 to 7 or a nutritional supplement of claim 9 for improving the bone mineralization in a mammal. A method of improving bone mineralization, preferably in a mammal, comprising; administering a composition of one of claims 1 to 7, a nutritional supplement of claim 9 or a pharmaceutical composition of claim 10 or 11. The method of claim 14, further comprising; decreasing a sclerostin level in a human osteoblasts treated with the said composition to improve bone health, and/or further comprising; increasing a core-binding factor alpha 1 level in human osteoblasts treated with the said composition to improve bone mineralization, and/or further comprising; increasing a level of alkaline phosphatase activity in human osteoblasts by treating with the said composition to improve bone mineralization.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/674,146 US11452710B1 (en) | 2022-02-17 | 2022-02-17 | Micronutrient and plant extract composition and method of improving bone health |
US17/674,146 | 2022-02-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023156956A1 true WO2023156956A1 (en) | 2023-08-24 |
Family
ID=83365596
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/051451 WO2023156956A1 (en) | 2022-02-17 | 2023-02-17 | Composition for improving bone health |
Country Status (2)
Country | Link |
---|---|
US (1) | US11452710B1 (en) |
WO (1) | WO2023156956A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11452710B1 (en) * | 2022-02-17 | 2022-09-27 | Matthias W. Rath | Micronutrient and plant extract composition and method of improving bone health |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110293759A1 (en) * | 2010-06-01 | 2011-12-01 | Calitoga Llc | Nutritional supplement for recovery, repair, and maintenance |
US11452710B1 (en) * | 2022-02-17 | 2022-09-27 | Matthias W. Rath | Micronutrient and plant extract composition and method of improving bone health |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7371389B2 (en) * | 2006-04-14 | 2008-05-13 | Arbonne International, Llc | Methods and products for enhancing energy and nutrition in human beings |
US11246899B2 (en) * | 2018-06-11 | 2022-02-15 | SynHiTech Inc. | Urtica dioica extracts and methods of isolating urtica dioica extracts |
GB2585619A (en) * | 2018-08-03 | 2021-01-20 | Prime Fifty Ltd | A supplement |
-
2022
- 2022-02-17 US US17/674,146 patent/US11452710B1/en active Active
-
2023
- 2023-02-17 WO PCT/IB2023/051451 patent/WO2023156956A1/en active Search and Examination
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110293759A1 (en) * | 2010-06-01 | 2011-12-01 | Calitoga Llc | Nutritional supplement for recovery, repair, and maintenance |
US11452710B1 (en) * | 2022-02-17 | 2022-09-27 | Matthias W. Rath | Micronutrient and plant extract composition and method of improving bone health |
Non-Patent Citations (6)
Title |
---|
ALJOHANI HANAN ET AL: "Methylsulfonylmethane Increases the Alveolar Bone Density of Mandibles in Aging Female Mice", FRONTIERS IN PHYSIOLOGY, vol. 12, 1 January 2021 (2021-01-01), pages 708905, XP093043438, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521043/pdf/fphys-12-708905.pdf> [retrieved on 20230502], DOI: 10.3389/fphys.2021.708905 * |
HECTOR L LOPEZ ED - FINNOFF JONATHAN T: "Nutritional Interventions to Prevent and Treat Osteoarthritis. Part II: Focus on Micronutrients and Supportive Nutraceuticals", PM&R, vol. 4, no. 5, 1 May 2012 (2012-05-01), pages S155 - S168, XP028506923, ISSN: 1934-1482, [retrieved on 20120301], DOI: 10.1016/J.PMRJ.2012.02.023 * |
IRGIN CELAL ET AL: "Does stinging nettle (Urtica dioica) have an effect on bone formation in the expanded inter-premaxillary suture?", ARCHIVES OF ORAL BIOLOGY, PERGAMON PRESS, OXFORD, GB, vol. 69, 7 May 2016 (2016-05-07), pages 13 - 18, XP029655466, ISSN: 0003-9969, DOI: 10.1016/J.ARCHORALBIO.2016.05.003 * |
RONDANELLI MARIANGELA ET AL: "Pivotal role of boron supplementation on bone health: A narrative review", JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, FISCHER, NEW YORK, NY, US, vol. 62, 6 June 2020 (2020-06-06), XP086332489, ISSN: 0946-672X, [retrieved on 20200606], DOI: 10.1016/J.JTEMB.2020.126577 * |
SAUDELLI GABRIELE ET AL: "A Review on the Treatment of Osteoporosis with Equisetum arvense", GENERAL MEDICINE: OPEN ACCESS, vol. 06, no. 02, 1 January 2018 (2018-01-01), XP055980272, Retrieved from the Internet <URL:https://www.biotecdermo.com.br/wp-content/uploads/2019/02/1.pdf> [retrieved on 20230502], DOI: 10.4172/2327-5146.1000313 * |
VIEGAS MICHAEL N ET AL: "Effect of Trace Minerals and B Vitamins on the Proliferation/Cytotoxicity and Mineralization of a Gilthead Seabream Bone-Derived Cell Line", BIOLOGICAL TRACE ELEMENT RESEARCH, HUMANA PRESS, CLIFTON, NJ, US, vol. 196, no. 2, 11 December 2019 (2019-12-11), pages 629 - 638, XP037174938, ISSN: 0163-4984, [retrieved on 20191211], DOI: 10.1007/S12011-019-01939-5 * |
Also Published As
Publication number | Publication date |
---|---|
US11452710B1 (en) | 2022-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9623042B2 (en) | Combination preparation for improving sperm quality | |
US20050261239A1 (en) | Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue | |
MX2007010492A (en) | Compounds having anti-cancer properties. | |
US20080234361A1 (en) | Pharmaceutical Compositions, Methods of Formulation Thereof and Methods of Use Thereof | |
CN110237089A (en) | The application of NADH and/or NMN prevention and treatment male erectile dysfunction | |
WO2023156956A1 (en) | Composition for improving bone health | |
JP2019529491A (en) | Alpha-ketobutyrate, alpha-ketoglutarate, and 2-hydroxybutyrate for stimulating hair growth | |
MX2008016125A (en) | Organic compounds. | |
US20240041821A1 (en) | 1,8-cineole containing composition for therapeutic use | |
US20220288050A1 (en) | Methods and compositions for the antiviral use of synthetic lysine analogs and mimetics | |
WO2006059714A1 (en) | Composition for prevention and/or treatment of bone diseases, physiologically functional or health foods containing the composition, and medicinal preparations containing the composition as the active ingredient | |
US20160339057A1 (en) | Novel composition method of using the same for the treatment of lyme disease | |
US20040105849A1 (en) | Treatment for SMA disease | |
WO2023012244A1 (en) | Combination therapy | |
WO2019106626A1 (en) | Composition for oral administration, the use of the composition in prevention and treatment of mucositis, and a method of treatment of mucositis | |
JP2020521785A (en) | Pharmaceutical composition for prevention or treatment of bone-related diseases | |
US20130172299A1 (en) | Combination Therapy for Treatment of Bone and Mineral Disorders for Patients with Impaired Renal Function | |
US11717013B1 (en) | Micronutrient combination to reduce blood pressure | |
US11666643B1 (en) | Micronutrient combination to reduce blood pressure | |
US11304921B1 (en) | Pharmaceutical micronutrient composition and its use to simultaneously treat nervous system function, cognitive ability and response to stressors | |
US11337959B1 (en) | Pharmaceutical composition Mix B to treat health conditions associated with elevated glucose levels | |
US11679096B1 (en) | Composition and method of treatment of elevated ApoE gene expression related health issues | |
WO2023037173A1 (en) | A pharmaceutical micronutrient composition for use to simultaneously improve nervous system function, cognitive ability and response to stressors | |
WO2023000247A1 (en) | APPLICATION OF α-ASARONE IN PREPARATION OF MEDICINE FOR PREVENTING OR TREATING HEMORRHAGIC STROKE | |
EP1518554B1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23708561 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |